Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: arnold silver who wrote (2739)	8/6/2003 12:38:47 PM
From: Ken W	Read Replies (1) \| Respond to of 23958

Arnie BLTI: If the customer buys at the full price after testing that is fine, but IF BLTI is booking the rev's at point of sale (full price) rather than the actual discount, then they are cooking the books. On the secondary offering: Dilution is just over 10% on the 2.5 mm shares, however there is nearly another 13% on excersise of warrants etc. at 3.69!! Jeez, what do you suppose the underwriter is going to do with those warrants that are 300% in the money? The number of shares of common stock outstanding after this offering is based on 21,475,322 shares outstanding as of June 9, 2003, and excludes 3,718,493 shares consisting of: • 2,844,280 shares issuable upon exercise of outstanding options at a weighted average exercise price of $3.69 per share; and • 874,213 additional shares of common stock reserved for future grant or issuance under our equity incentive compensation plans. Unless otherwise indicated, all information in this prospectus assumes no exercise by the underwriters of their over-allotment option to purchase up to 307,500 additional shares of common stock from one of our stockholders, American Medical Technologies, Inc., and up to 67,500 additional shares of common stock from us. Shares purchased by the underwriters to cover over-allotments, if any, will be offered for sale under this prospectus. We will not receive any proceeds from the sale of shares by the selling stockholder. Ken